Cardiovascular disease in inflammatory rheumatic diseases

Best Practice and Research: Clinical Rheumatology

Volumn 30, Issue 5, 2016, Pages 851-869

  Castañeda, Santos ^a   Nurmohamed, Michael T ^b   González Gay, Miguel A ^c  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Ankylosing spondylitis; Cardiovascular disease; Cardiovascular risk assessment; Cardiovascular risk factors; Psoriatic arthritis; Rheumatoid arthritis; Spondyloarthritis

Indexed keywords

CORTICOSTEROID; NONSTEROID ANTIINFLAMMATORY AGENT;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ACTIVITY; GENETICS; HUMAN; INFLAMMATORY DISEASE; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; STANDARDIZED MORTALITY RATIO; THROMBOSIS; VULNERABLE POPULATION; CARDIOVASCULAR DISEASES; COMPLICATION; PREVALENCE;

CARDIOVASCULAR DISEASES; HUMANS; PREVALENCE; RHEUMATIC DISEASES;

EID: 85003587560     PISSN: 15216942     EISSN: 15321770     Source Type: Journal    
DOI: 10.1016/j.berh.2016.10.006     Document Type: Review

References (150)

1. Agca, R., Heslinga, S.C., van Halm, V.P., Nurmohamed, M.T., Atherosclerotic cardiovascular disease in patients with chronic inflammatory joint disorders. Heart 102 (2016), 790–795.
2. [2] Castañeda, S., Martín-Martínez, M.A., González-Juanatey, C., et al. CARMA Project Collaborative Group. Cardiovascular morbidity and associated risk factors in Spanish patients with chronic inflammatory rheumatic diseases attending rheumatology clinics: baseline data of the CARMA Project. Semin Arthritis Rheum 44 (2015), 618–626.
3. [3] Van den Hoek, J., Roorda, L.D., Boshuizen, H.C., et al. Trend in and predictors for cardiovascular mortality in patients with rheumatoid arthritis over a period of 15 years: a prospective cohort study. Clin Exp Rheumatol 34 (2016), 813–819.
4. Aviña-Zubieta, J.A., Choi, H.K., Sadatsafavi, M., et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 59 (2008), 1690–1697.
5. [5] Avina-Zubieta, J.A., Thomas, J., Sadatsafavi, M., et al. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 71 (2012), 1524–1529.
6. [6] Lindhardsen, J., Ahlehoff, O., Gislason, G.H., et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis 70 (2011), 929–934.
7. [7] van Halm, V.P., Peters, M.J., Voskuyl, A.E., et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis 68 (2009), 1395–1400.
8. [8] Peters, M.J., van Halm, V.P., Voskuyl, A.E., et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 61 (2009), 1571–1579.
9. [9] Maradit-Kremers, H., Crowson, C.S., Nicola, P.J., et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 52 (2005), 402–411.
10. [10] Prati, C., Claudepierre, P., Pham, T., Wendling, D., Mortality in spondylarthritis. Jt Bone Spine 78 (2011), 466–470.
11. [11] Han, C., Robinson, D.W. Jr., Hackett, M.V., et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33 (2006), 2167–2172.
12. [12] Szabo, S.M., Levy, A.R., Rao, S.R., et al. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum 63 (2011), 3294–3304.
13. [13] Peters, M.J., Visman, I., Nielen, M.M., et al. Ankylosing spondylitis: a risk factor for myocardial infarction?. Ann Rheum Dis 69 (2010), 579–581.
14. [14] Mathieu, S., Pereira, B., Soubrier, M., Cardiovascular events in ankylosing spondylitis: an updated meta-analysis. Semin Arthritis Rheum 44 (2015), 551–555.
15. [15] Dauden, E., Castañeda, S., Suárez, C., et al., Working Group on Comorbidity in Psoriasis. Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. J Eur Acad Dermatol Venereol 27 (2013), 1387–1404.
16. [16] Mallbris, L., Arke, O., Granath, F., et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 19 (2004), 225–230.
17. [17] Ogdie, A., Yu, Y., Haynes, K., et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis 74 (2015), 326–332.
18. [18] Ahlehoff, O., Gislason, G.H., Charlot, M., et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 270 (2011), 147–157.
19. [19] Jamnitski, A., Visman, I.M., Peters, M.J., et al. Prevalence of cardiovascular diseases in psoriatic arthritis resembles that of rheumatoid arthritis. Ann Rheum Dis 1:70 (2010), 284–288.
20. [20] Ernste, F.C., Sánchez-Menéndez, M., Wilton, K.M., et al. Cardiovascular risk profile at the onset of psoriatic arthritis: a population-based cohort study. Arthritis Care Res (Hoboken) 67 (2015), 1015–1021.
21. [21] Kerekes, G., Soltész, P., Nurmohamed, M.T., et al. Validated methods for assessment of subclinical atherosclerosis in rheumatology. Nat Rev Rheumatol 8 (2012), 224–234.
22. [22] Gonzalez-Juanatey, C., Testa, A., Garcia-Castelo, A., et al. HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med 114 (2003), 647–652.
23. [23] Vaudo, G., Marchesi, S., Gerli, R., et al. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 63 (2004), 31–35.
24. [24] Bodnár, N., Kerekes, G., Seres, I., et al. Assessment of subclinical vascular disease associated with ankylosing spondylitis. J Rheumatol 38 (2011), 723–729.
25. [25] Gonzalez-Juanatey, C., Llorca, J., Miranda-Filloy, J.A., et al. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 57 (2007), 287–293.
26. [26] González-Juanatey, C., Llorca, J., González-Gay, M.A., Correlation between endothelial function and carotid atherosclerosis in rheumatoid arthritis patients with longstanding disease. Arthritis Res Ther, 13, 2011, R101.
27. [27] Gonzalez-Juanatey, C., Llorca, J., Martin, J., Gonzalez-Gay, M.A., Carotid intima-media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis. Semin Arthritis Rheum 38 (2009), 366–371.
28. [28] Evans, M.R., Escalante, A., Battafarano, D.F., et al. Carotid atherosclerosis predicts incident acute coronary syndromes in rheumatoid arthritis. Arthritis Rheum 63 (2011), 1211–1220.
29. [29] van Sijl, A.M., Peters, M.J., Knol, D.K., et al. Carotid intima media thickness in rheumatoid arthritis as compared to control subjects: a meta-analysis. Semin Arthritis Rheum 40 (2011), 389–397.
30. Ambrosino, P., Lupoli, R., Di Minno, A., et al. Subclinical atherosclerosis in patients with rheumatoid arthritis. A meta-analysis of literature studies. Thromb Haemost 113 (2015), 916–930.
31. [31] Gonzalez-Gay, M.A., Gonzalez-Juanatey, C., Piñeiro, A., et al. High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol 32 (2005), 1219–1223.
32. [32] Corrales, A., González-Juanatey, C., Peiró, M.E., et al. Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study. Ann Rheum Dis 73 (2014), 722–727.
33. [33] Corrales, A., Parra, J.A., González-Juanatey, C., et al. Cardiovascular risk stratification in rheumatic diseases: carotid ultrasound is more sensitive than coronary artery calcification score to detect subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis 72 (2013), 1764–1770.
34. [34] Gerli, R., Bartoloni Bocci, E., Sherer, Y., et al. Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis 67 (2008), 724–725.
35. [35] Peters, M.J., van Eijk, I.C., Smulders, Y.M., et al. Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 37 (2010), 161–166.
36. [36] Gonzalez-Juanatey, C., Vazquez-Rodriguez, T.R., Miranda-Filloy, J.A., et al. The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Med (Baltimore) 88 (2009), 358–365.
37. [37] Gonzalez-Juanatey, C., Llorca, J., Amigo-Diaz, E., et al. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 57 (2007), 1074–1080.
38. [38] Di Minno, M.N., Iervolino, S., Peluso, R., et al., CaRRDs study group. Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-α blockers and traditional disease-modifying antirheumatic drugs. Arterioscler Thromb Vasc Biol 31 (2011), 705–712.
39. Liao, K.P., Solomon, D.H., Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Rheumatol (Oxford) 52 (2013), 45–52.
40. Sen, D., González-Mayda, M., Brasington, R.D. Jr., Cardiovascular disease in rheumatoid arthritis. Rheum Dis Clin North Am 40 (2014), 27–49.
41. Giles, J.T., Cardiovascular disease in rheumatoid arthritis: current perspectives on assessing and mitigating risk in clinical practice. Best Pract Res Clin Rheumatol 29 (2015), 597–613.
42. [42] Bergstrom, U., Jacobsson, L.T., Nilsson, J.A., et al. Pulmonary dysfunction, smoking, socioeconomic status and the risk of developing rheumatoid arthritis. Rheumatol (Oxford) 50 (2011), 2005–2013.
43. [43] Nurmohamed, M.T., Cardiovascular risk in rheumatoid arthritis. Autoimmun Rev 8 (2009), 663–667.
44. [44] Solomon, D.H., Love, T.J., Canning, C., Schneeweiss, S., Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. Ann Rheum Dis 69 (2010), 2114–2117.
45. Jamnitski, A., Symmons, D., Peters, M.J., et al. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis 72 (2013), 211–216.
46. [46] Zhang, J., Fu, L., Shi, J., et al. The risk of metabolic syndrome in patients with rheumatoid arthritis: a meta-analysis of observational studies. PLoS One, 8, 2013, e78151.
47. [47] Ferraz-Amaro, I., González-Juanatey, C., López-Mejias, R., et al. Metabolic syndrome in rheumatoid arthritis. Mediat Inflamm, 7, 2013, 10928.
48. [48] Gonzalez-Gay, M.A., Gonzalez-Juanatey, C., Vazquez-Rodriguez, T.R., et al. Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy. Ann N. Y Acad Sci 1193 (2010), 153–159.
49. [49] Miranda-Filloy, J.A., Llorca, J., Carnero-López, B., et al. TNF-alpha antagonist therapy improves insulin sensitivity in non-diabetic ankylosing spondylitis patients. Clin Exp Rheumatol 30 (2012), 850–855.
50. [50] Schultz, O., Oberhauser, F., Saech, J., et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS One, 5, 2010, e14328.
51. [51] Wisse, B.E., The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 15 (2004), 2792–2800.
52. [52] Ridker, P.M., Buring, J.E., Rifai, N., Cook, N.R., Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 297 (2007), 611–619.
53. [53] Giles, J.T., Bartlett, S.J., Andersen, R., et al. Association of body fat with C-reactive protein in rheumatoid arthritis. Arthritis Rheum 58 (2008), 2632–2641.
54. [54] Maradit Kremers, H.M., Nicola, P.J., Crowson, C.S., et al. Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum 50 (2004), 3450–3457.
55. [55] Summers, G.D., Metsios, G.S., Stavropoulos-Kalinoglou, A., Kitas, G.D., Rheumatoid cachexia and cardiovascular disease. Nat Rev Rheumatol 6 (2010), 445–451.
56. [56] Mok, C.C., Ko, G.T., Ho, L.Y., et al. Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken) 63 (2011), 195–202.
57. [57] Kimhi, O., Caspi, D., Bornstein, N.M., et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 36 (2007), 203–209.
58. [58] Panoulas, V.F., Douglas, K.M., Milionis, H.J., et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatol (Oxford) 46 (2007), 1477–1482.
59. [59] Chung, C.P., Giles, J.T., Petri, M., et al. Prevalence of traditional modifiable cardiovascular risk factors in patients with rheumatoid arthritis: comparison with control subjects from the multi-ethnic study of atherosclerosis. Semin Arthritis Rheum 41 (2012), 535–544.
60. [60] Boyer, J.F., Gourraud, P.A., Cantagrel, A., et al. Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Jt Bone Spine 78 (2011), 179–183.
61. [61] Tam, L.S., Tomlinson, B., Chu, T.T., et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls–the role of inflammation. Rheumatol (Oxford) 47 (2008), 718–723.
62. [62] González-Gay, M.A., González-Juanatey, C., Inflammation and lipid profile in rheumatoid arthritis: bridging an apparent paradox. Ann Rheum Dis 73 (2014), 1281–1283.
63. [63] Myasoedova, E., Crowson, C.S., Kremers, H.M., et al. Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann Rheum Dis 69 (2010), 1310–1314.
64. [64] Charles-Schoeman, C., Watanabe, J., Lee, Y.Y., et al. Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum 60 (2009), 2870–2879.
65. [65] Charles-Schoeman, C., Lee, Y.Y., Grijalva, V., et al. Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann Rheum Dis 71 (2012), 1157–1162.
66. [66] Hurt-Camejo, E., Paredes, S., Masana, L., et al. Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile. Arthritis Rheum 44 (2001), 2761–2767.
67. [67] Mathieu, S., Motreff, P., Soubrier, M., Spondyloarthropathies: an independent cardiovascular risk factor?. Jt Bone Spine 77 (2010), 542–545.
68. [68] Papagoras, C., Voulgari, P.V., Drosos, A.A., Atherosclerosis and cardiovascular disease in the spondyloarthritides, particularly ankylosing spondylitis and psoriatic arthritis. Clin Exp Rheumatol 31 (2013), 612–620.
69. [69] John, H., Kitas, G., Inflammatory arthritis as a novel risk factor for cardiovascular disease. Eur J Intern Med 23 (2012), 575–579.
70. [70] van Halm, V.P., van Denderen, J.C., Peters, M.J., et al. Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis. Ann Rheum Dis 65 (2006), 1473–1477.
71. [71] van Eijk, I.C., de Vries, M.K., Levels, J.H., et al. Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis. Arthritis Rheum 60 (2009), 1324–1330.
72. [72] van Sijl, A.M., Peters, M.J., Knol, D.L., et al. The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis. Semin Arthritis Rheum 41 (2011), 393–400.
73. [73] Maini, R.N., Taylor, P.C., Szechinski, J., et al., CHARISMA Study Group. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54 (2006), 2817–2829.
74. [74] Charles-Schoeman, C., Gonzalez-Gay, M.A., Kaplan, I., et al. Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist. Semin Arthritis Rheum 46 (2016), 71–80.
75. [75] Morris, S.J., Wasko, M.C., Antohe, J.L., et al. Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 63 (2011), 530–534.
76. [76] Semb, A.G., Rollefstad, S., Spondyloarthropathies: CVD prevention and statin therapy in ankylosing spondylitis. Nat Rev Rheumatol 12 (2016), 441–442.
77. [77] Kremers, H.M., Crowson, C.S., Therneau, T.M., et al. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study. Arthritis Rheum 58 (2008), 2268–2274.
78. [78] Young, A., Koduri, G., Batley, M., et al. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatol (Oxford) 46 (2007), 350–357.
79. [79] Kao, A.H., Krishnaswami, S., Cunningham, A., et al. Subclinical coronary artery calcification and relationship to disease duration in women with rheumatoid arthritis. J Rheumatol 35 (2008), 61–69.
80. [80] Liang, K.P., Kremers, H.M., Crowson, C.S., et al. Autoantibodies and the risk of cardiovascular events. J Rheumatol 36 (2009), 2462–2469.
81. [81] Goodson, N.J., Wiles, N.J., Lunt, M., et al. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 46 (2002), 2010–2019.
82. [82] Crowson, C.S., Therneau, T.M., Davis, J.M. 3rd, et al. Brief report: accelerated aging influences cardiovascular disease risk in rheumatoid arthritis. Arthritis Rheum 65 (2013), 2562–2566.
83. [83] Goodson, N.J., Symmons, D.P., Scott, D.G., et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year follow-up study of a primary care-based inception cohort. Arthritis Rheum 52 (2005), 2293–2299.
84. [84] Banerjee, S., Compton, A.P., Hooker, R.S., et al. Cardiovascular outcomes in male veterans with rheumatoid arthritis. Am J Cardiol 101 (2008), 1201–1205.
85. [85] Gonzalez-Gay, M.A., Gonzalez-Juanatey, C., Lopez-Diaz, M.J., et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 57 (2007), 125–132.
86. [86] Gonzalez-Gay, M.A., Gonzalez-Juanatey, C., Vazquez-Rodriguez, T.R., et al. Asymptomatic hyperuricemia and serum uric acid concentration correlate with subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease. Semin Arthritis Rheum 39 (2009), 157–1562.
87. [87] Daoussis, D., Kitas, G.D., Uric acid and cardiovascular risk in rheumatoid arthritis. Rheumatol (Oxford) 50 (2011), 1354–1355.
88. [88] Panoulas, V.F., Milionis, H.J., Douglas, K.M., et al. Association of serum uric acid with cardiovascular disease in rheumatoid arthritis. Rheumatol (Oxford) 46 (2007), 1466–1470.
89. [89] Trelle, S., Reichenbach, S., Wandel, S., et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ, 342, 2011, c7086.
90. [90] Lindhardsen, J., Gislason, G.H., Jacobsen, S., et al. Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis 73 (2014), 1515–1521.
91. [91] Aviña-Zubieta, J.A., Abrahamowicz, M., De Vera, M.A., et al. Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. Rheumatol (Oxford) 52 (2013), 68–75.
92. [92] Aviña-Zubieta, J.A., Abrahamowicz, M., Choi, H.K., et al. Risk of cerebrovascular disease associated with the use of glucocorticoids in patients with incident rheumatoid arthritis: a population-based study. Ann Rheum Dis 70 (2011), 990–995.
93. [93] Davis, J.M. 3rd, Maradit Kremers, H., Crowson, C.S., et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 56 (2007), 820–830.
94. [94] Choi, H.K., Hernán, M.A., Seeger, J.D., et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359 (2002), 1173–1177.
95. [95] Barnabe, C., Martin, B.J., Ghali, W.A., Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 63 (2011), 522–529.
96. López-Mejías, R., Castañeda, S., González-Juanatey, C., et al. Cardiovascular risk assessment in patients with rheumatoid arthritis: the relevance of clinical, genetic and serological markers. Autoimmun Rev 15 (2016), 1013–1030.
97. [97] Farragher, T.M., Goodson, N.J., Naseem, H., et al. Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis Rheum 58 (2008), 359–369.
98. [98] Rojas-Villarraga, A., Ortega-Hernandez, O.D., Gomez, L.F., et al. Risk factors associated with different stages of atherosclerosis in Colombian patients with rheumatoid arthritis. Semin Arthritis Rheum 38 (2008), 71–82.
99. [99] Rodríguez-Rodríguez, L., González-Juanatey, C., Palomino-Morales, R., et al. TNFA -308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis 216 (2011), 125–130.
100. [100] Palomino-Morales, R., Gonzalez-Juanatey, C., Vazquez-Rodriguez, T.R., et al. A1298C polymorphism in the MTHFR gene predisposes to cardiovascular risk in rheumatoid arthritis. Arthritis Res Ther, 12, 2010, R71.
101. [101] López-Mejías, R., Genre, F., Remuzgo-Martínez, S., et al. Vitamin D receptor GATG haplotype association with atherosclerotic disease in patients with rheumatoid arthritis. Atherosclerosis 245 (2016), 139–142.
102. [102] García-Bermúdez, M., López-Mejías, R., Genre, F., et al. Interferon regulatory factor 5 genetic variants are associated with cardiovascular disease in patients with rheumatoid arthritis. Arthritis Res Ther, 16, 2014, R146.
103. [103] López-Mejías, R., García-Bermúdez, M., González-Juanatey, C., et al. NFKB1-94ATTG ins/del polymorphism (rs28362491) is associated with cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis 224 (2012), 426–429.
104. [104] López-Mejías, R., Genre, F., Remuzgo-Martínez, S., et al. Influence of elevated-CRP level-related polymorphisms in non-rheumatic Caucasians on the risk of subclinical atherosclerosis and cardiovascular disease in rheumatoid arthritis. Sci Rep, 6, 2016, 31979, 10.1038/srep31979.
105. [105] Libby, P., Ridker, P.M., Hansson, G.K., Progress and challenges in translating the biology of atherosclerosis. Nature 473 (2011), 317–325.
106. [106] Kaptoge, S., Di Angelantonio, E., Lowe, G., et al., Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375 (2010), 132–140.
107. [107] Libby, P., Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med 121:Suppl. 1 (2008), S21–S31.
108. [108] Myasoedova, E., Crowson, C.S., Kremers, H.M., et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 70 (2011), 482–487.
109. [109] de Groot, L., Posthumus, M.D., Kallenberg, C.G., Bijl, M., Risk factors and early detection of atherosclerosis in rheumatoid arthritis. Eur J Clin Invest 40 (2010), 835–842.
110. [110] Greenberg, J.D., Furer, V., Farkouh, M.E., Cardiovascular safety of biologic therapies for the treatment of RA. Nat Rev Rheumatol 8 (2012), 13–21.
111. [111] Ridker, P.M., Buring, J.E., Shih, J., et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98 (1998), 731–733.
112. [112] Biasucci, L.M., Liuzzo, G., Fantuzzi, G., et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 99 (1999), 2079–2084.
113. [113] Ridker, P.M., Rifai, N., Stampfer, M.J., Hennekens, C.H., Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101 (2000), 1767–1772.
114. [114] Popa, C.D., Arts, E., Fransen, J., van Riel, P.L., Atherogenic index and high-density lipoproteincholesterol as cardiovascular risk determinants in rheumatoid arthritis: theimpact of therapy with biologicals. Mediat Inflamm, 2012, 2012, 785946.
115. [115] Choy, E., Ganeshalingam, K., Semb, A.G., et al. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatol (Oxford) 53 (2014), 2143–2154.
116. Sidibé, A., Mannic, T., Arboleas, M., et al. Soluble VE-cadherin in rheumatoid arthritis patients correlates with disease activity: evidence for tumor necrosis factor α-induced VE-cadherin cleavage. Arthritis Rheum 64 (2012), 77–87.
117. [117] Missala, I., Kassner, U., Steinhagen-Thiessen, E., A systematic literature review the association of lipoprotein(a) and autoimmune diseases and atherosclerosis. Int J Rheumatol, 2012, 2012, 480784.
118. [118] van Breukelen-van der Stoep, D.F., Klop, B., van Zeben, D., et al. Cardiovascular risk in rheumatoid arthritis: how to lower the risk?. Atherosclerosis 231 (2013), 163–172.
119. [119] Aubry, M.C., Maradit-Kremers, H., Reinalda, M.S., et al. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J Rheumatol 34 (2007), 937–942.
120. [120] Semb, A.G., Rollefstad, S., Provan, S.A., et al. Carotid plaque characteristics and disease activity in rheumatoid arthritis. J Rheumatol 40 (2013), 359–368.
121. [121] Russolillo, A., Iervolino, S., Peluso, R., et al. Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management. Rheumatol (Oxford) 52 (2013), 62–67.
122. [122] Crowson, C.S., Nicola, P.J., Maradit Kremers, H., et al. How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease?. Arthritis Rheum 52 (2005), 3039–3044.
123. [123] Martín-Martínez, M.A., González-Juanatey, C., Castañeda, S., et al. Recommendations for the management of cardiovascular risk in patients with rheumatoid arthritis: scientific evidence and expert opinion. Semin Arthritis Rheum 44 (2014), 1–8.
124. [124] Emanuel, G., Charlton, J., Ashworth, M., et al. Cardiovascular risk assessment and treatment in chronic inflammatory disorders in primary care. Heart, 2016 Aug 17, 10.1136/heartjnl-2016-310111 pii: heartjnl-2016-310111. [Epub ahead of print].
125. [125] González-Gay, M.A., González-Juanatey, C., Cardiovascular risk factor assessment: still an unmet need in chronic inflammatory diseases. Heart, 2016 Aug 18, 10.1136/heartjnl-2016-310292 pii: heartjnl-2016-310292. [Epub ahead of print].
126. [126] Peters, M.J., Symmons, D.P., McCarey, D., et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69 (2010), 325–331.
127. [127] Agca, R., Heslinga, S.C., Rollefstad, S., et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis, 2016 Oct 3.
128. Soubrier, M., Barber Chamoux, N., Tatar, Z., et al. Cardiovascular risk in rheumatoid arthritis. Jt Bone Spine 81 (2014), 298–302.
129. [129] Loza, E., Lajas, C., Andreu, J.L., et al. Consensus statement on a framework for the management of comorbidity and extra-articular manifestations in rheumatoid arthritis. Rheumatol Int 35 (2015), 445–458.
130. [130] Panoulas, V.F., Metsios, G.S., Pace, A.V., et al. Hypertension in rheumatoid arthritis. Rheumatol (Oxford) 47 (2008), 1286–1298.
131. [131] Provan, S.A., Semb, A.G., Hisdal, J., et al. Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study. Ann Rheum Dis 70 (2011), 812–817.
132. [132] Micha, R., Imamura, F., Wyler von Ballmoos, M., et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 108 (2011), 1362–1370.
133. [133] Everett, B.M., Pradhan, A.D., Solomon, D.H., et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J 166 (2013), 199–207 e15.
134. [134] Greenberg, J.D., Kremer, J.M., Curtis, J.R., et al., CORRONA Investigators. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 70 (2011), 576–582.
135. [135] Ljung, L., Simard, J.F., Jacobsson, L., et al., Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group. Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis. Arthritis Rheum 64 (2012), 42–52.
136. [136] Gómez-Vaquero, C., Corrales, A., Zacarías, A., et al. SCORE and REGICOR function charts underestimate the cardiovascular risk in Spanish patients with rheumatoid arthritis. Arthritis Res Ther, 15, 2013, R91.
137. [137] Rueda-Gotor, J., Llorca, J., Corrales, A., et al. Carotid ultrasound in the cardiovascular risk stratification of patients with ankylosing spondylitis: results of a population-based study. Clin Exp Rheumatol 34 (2016), 885–892.
138. [138] Eder, L., Gladman, D.D., Atherosclerosis in psoriatic disease: latest evidence and clinical implications. Ther Adv Musculoskelet Dis 7 (2015), 187–195.
139. [139] Hippisley-Cox, J., Coupland, C., Vinogradova, Y., et al. Performance Of the QRISK cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: a validation study. Heart 94 (2008), 34–39.
140. [140] Solomon, D.H., Greenberg, J., Curtis, J.R., et al. Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: a Consortium of Rheumatology Researchers of North America Registry Study. Arthritis Rheumatol 67 (2015), 1995–2003.
141. [141] Corrales, A., Dessein, P.H., Tsang, L., et al. Carotid artery plaque in women with rheumatoid arthritis and low estimated cardiovascular disease risk: a cross-sectional study. Arthritis Res Ther, 17, 2015, 55, 10.1186/s13075-015-0576-7.
142. [142] Wiersma, T., Smulders, Y.M., Stehouwer, C.D., et al. Summary of the multidisciplinary guideline on cardiovascular risk management (revision 2011). Ned Tijdschr Geneeskd, 156, 2012, A5104 [Article in Dutch].
143. [143] González-Gay, M.A., González-Juanatey, C., Llorca, J., Carotid ultrasound in the cardiovascular risk stratification of patients with rheumatoid arthritis: when and for whom?. Ann Rheum Dis 71 (2012), 796–798.
144. [144] Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent, C., Blackwell, L., Emberson, J., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376 (2010), 1670–1681.
145. [145] Semb, A.G., Holme, I., Kvien, T.K., Pedersen, T.R., Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial. Rheumatol (Oxford) 50 (2011), 324–329.
146. [146] Piepoli, M.F., Hoes, A.W., Agewall, S., et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European association for cardiovascular prevention & rehabilitation (EACPR). Eur Heart J 37 (2016 Aug 1), 2315–2381.
147. [147] Toms, T.E., Panoulas, V.F., Douglas, K.M., et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk?. Ann Rheum Dis 69 (2010), 683–688.
148. Akkara Veetil, B.M., Myasoedova, E., Matteson, E.L., et al. Use of lipid-lowering agents in rheumatoid arthritis: a population-based cohort study. J Rheumatol 40 (2013), 1082–1088.
149. [149] De Vera, M.A., Choi, H., Abrahamowicz, M., et al. Statin discontinuation and risk of acute myocardial infarction in patients with rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis 70 (2011), 1020–1024.
150. [150] Law, M.R., Morris, J.K., Wald, N.J., Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ, 338, 2009, b1665.